Valbenazine is applied across domains where additional symptomatic support for involuntary motor issues is needed. Valbenazine is commonly used for managing symptoms associated with two movement disorders in adults: tardive dyskinesia (TD) and chorea associated with Huntington's disease (HD). This medication helps provide supportive relief when symptoms that interfere with daily functioning are present, contributing to easing the overall symptom load.

Targeting Involuntary Movements of Tardive Dyskinesia

Valbenazine is commonly used to help with tardive dyskinesia (TD), a condition where symptoms of increased neurological or muscular activity create noticeable physiological strain. It assists in managing symptom clusters that may become intense or disruptive, such as movements of the face (grimacing, lip smacking), tongue, and the extremities. The medication may assist with easing the symptom load, which is relevant for managing the severity and frequency of these involuntary movements.

Moderation of Chorea in Huntington's Disease

The drug is also considered relevant for easing the symptoms of chorea associated with Huntington's disease (HD). This applies in clinical settings that involve acute or unstable symptom patterns, where the choreiform movements, which are irregular, flowing, and unpredictable jerking, may affect functional stability. Valbenazine may be part of symptomatic management that contributes to easing distress and assists with maintaining functional stability when movements are more noticeable.

---

Quick Fact: Symptomatic Support for Involuntary Motor Symptoms

Valbenazine is a prescription medicine approved for adults only, and its use is strictly governed by regulatory rules regarding allergies, pre-existing health conditions, and specific physiological states.

Official Eligibility Constraints

Classification	Who Cannot Use or Must Use with Restrictions
Absolute Contraindication	Patients with a history of hypersensitivity to valbenazine or any product components.
Avoid Use	Patients with congenital long QT syndrome or arrhythmias associated with a prolonged QT interval.
Age Restriction	Safety and effectiveness have not been established in pediatric patients (under 18 years of age).
Organ/Metabolic Restriction	Use is not recommended in severe renal impairment (creatinine clearance <30 mL/ min). The maximum daily dosage is restricted in patients with moderate to severe hepatic impairment and in those identified as CYP2D6 poor metabolizers.
Physiological State	Breastfeeding is not recommended during treatment and for 5 days after the final dose. Pregnancy data are insufficient, and animal studies suggest potential fetal harm.

Valbenazine is subject to several documented drug interactions that require specific restrictions or monitoring based on its metabolic profile and inhibitory activity.

Official Interaction Restrictions

Interacting Product Category	Restriction or Requirement
Monoamine Oxidase Inhibitors (MAOIs) (e.g., phenelzine, selegiline)	Avoid concomitant use. Do not use Valbenazine within 14 days of discontinuing an MAOI.
Strong CYP3A4 Inducers (e.g., rifampin, St. John’s wort)	Concomitant use is not recommended. These products significantly decrease exposure to Valbenazine and its active metabolite.
Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin)	Dose reduction is required. The Valbenazine dosage must be reduced when coadministered with a strong CYP3A4 inhibitor, as these increase exposure.
Strong CYP2D6 Inhibitors (e.g., paroxetine, quinidine)	Dose reduction may be necessary based on patient tolerability, due to increased exposure to the active metabolite, which may increase the risk of QT prolongation.
P-glycoprotein (P-gp) Substrates (e.g., digoxin)	Monitoring is required. Valbenazine may inhibit P-gp, which can increase the concentration of co-administered P-gp substrates, requiring monitoring of the substrate’s concentration.

The mechanistic basis for these restrictions is the metabolism of Valbenazine, which involves the CYP3A4/5 enzymes, and the metabolism of its active metabolite by CYP2D6. Altering the activity of these enzymes, or inhibiting the P-gp transporter, changes the drug's exposure. Patients who are genetically identified as CYP2D6 poor metabolizers also require a dose adjustment due to anticipated higher exposure of the active metabolite, mirroring the effect of strong CYP2D6 inhibitors.

Mechanism of Action: Presynaptic Dopamine Modulation

Valbenazine acts primarily via its active metabolite as a selective, competitive inhibitor of the Vesicular Monoamine Transporter 2 ( VMAT2) protein. This mechanism is confined to monoaminergic pathways within the central nervous system, where VMAT2 is responsible for pumping neurotransmitters, predominantly dopamine, into storage vesicles inside nerve terminals.

Blocking VMAT2 disrupts the packaging process, leading to the accumulation of free dopamine in the neuron's cytoplasm. This dopamine is subsequently broken down by catabolic enzymes, resulting in a depletion of the readily releasable neurotransmitter pool. This presynaptic interference alters dopaminergic signaling dynamics in affected neural circuits. The system-level consequence is a controlled modulation of signal output and an adjustment of the balance of neurotransmission, modifying early molecular steps that shape downstream physiological outcomes.

Valbenazine is administered orally once daily. The dose is initiated at 40 mg and then increased to the recommended dose of 80 mg once daily, following a specific schedule determined by the medical condition.

Official Dosing and Administration

Usage Condition	Initial Dose	Maintenance/Recommended Dose
Tardive Dyskinesia	40 mg once daily	80 mg once daily (after one week)
Chorea (Huntington's Disease)	40 mg once daily	Increase by 20 mg every two weeks, up to 80 mg once daily

The medicine can be taken with or without food. If you miss a dose, you should skip the missed dose and resume your regular dosing schedule the next day. You must not take two doses to compensate for the one you missed.

Dosage Adjustments and Special Use

Specific dosage limits are required for certain patient groups to ensure correct drug exposure:

• Hepatic Impairment: The maximum recommended dose for patients with moderate or severe liver problems (hepatic impairment) is 40 mg once daily.
• CYP2D6 Metabolism: Patients identified as known CYP2D6 poor metabolizers or who are taking a strong CYP2D6 inhibitor should not exceed 40 mg once daily. Similar dose reduction to 40 mg once daily is required when taking a strong CYP3A4 inhibitor.

Capsule Preparation

If the capsule is swallowed whole, it is taken directly by mouth. For the alternative Sprinkle formulation, the capsule may be opened, and its entire contents sprinkled onto one tablespoon of soft food (such as applesauce, yogurt, or pudding). The drug/food mixture must be swallowed immediately, or within two hours of preparation.

Valbenazine: Recent Clinical Evidence

Research has explored valbenazine's profile in adults for the management of tardive dyskinesia. Studies have investigated its effect on abnormal involuntary movements, which were assessed using standardized rating scales, such as the Abnormal Involuntary Movement Scale (AIMS).

Primary Study Goals and Findings

Clinical trials examined whether treatment with valbenazine was associated with a change in the severity of involuntary movements in participants over periods typically ranging from six weeks to one year. These trials were predominantly randomized, placebo-controlled designs.

Key studies focused on the reduction in AIMS total scores from the start of the study to a pre-defined point, usually Week 6. Findings from these trials consistently suggest that participants receiving the study drug experienced a greater reduction in AIMS scores compared to participants receiving placebo. Evidence remains limited regarding the long-term changes in movement severity beyond one year of treatment.

Administration and Limitations

Research evaluated a fixed daily dose regimen. Studies did not examine the effects of suddenly stopping treatment, and findings from research suggest that an abrupt discontinuation may be associated with a recurrence or worsening of the condition.

Research evaluated the profile of the drug in most people, but certain participant groups, such as those with pre-existing severe liver impairment, were generally excluded from clinical trials. Overall, research evaluated its use in participants with established tardive dyskinesia.

Common questions about Valbenazine (FAQ)

Q: Does Valbenazine affect driving or operating machinery?

According to official prescribing information, valbenazine may impair a person’s ability to drive or operate complex machinery. This warning is due to the potential for side effects like drowsiness and somnolence, which are common. The official product information advises caution regarding these activities until the individual knows their personal response to the medication.

Q: Can Valbenazine be crushed or split if someone has trouble swallowing pills?

Valbenazine is administered as a capsule that may be swallowed whole. Official instructions describe an alternative method for use where the capsule may be opened, and its contents sprinkled onto one tablespoon of soft food, such as applesauce or yogurt, and swallowed right away. The product information states that the granules should not be crushed or chewed when preparing this mixture.

Q: How long do most people stay on Valbenazine treatment?

Valbenazine is approved for the ongoing management of tardive dyskinesia. Clinical evidence suggests that the medicine's benefits are maintained with continued treatment for periods longer than one year. Research indicates that symptoms tend to return after the medication is discontinued, suggesting that ongoing treatment is necessary to maintain symptom management.

Q: What are the most common reasons why people stop taking Valbenazine?

Official regulatory documents list several conditions that may require discontinuation or dose reduction. These include the potential for serious adverse reactions such as Neuroleptic Malignant Syndrome (NMS) or hypersensitivity. The prescribing information notes that treatment may be discontinued due to the emergence or worsening of Parkinson-like symptoms, or if adverse reactions like restlessness (akathisia) or somnolence become clinically significant.

Q: Are there any requirements for monitoring while taking Valbenazine?

Official prescribing information outlines specific safety concerns for which patients may be monitored while using valbenazine. This includes checking for signs of new or worsening Parkinson-like symptoms (Parkinsonism) and hypersensitivity reactions. For patients with certain cardiac risk factors, evaluation of the heart's electrical activity (QT interval) may be necessary before dose changes.

Q: Does Valbenazine have potential for misuse or dependence? / Is Valbenazine considered a controlled substance?

Valbenazine is a prescription-only medicine. According to the U.S. Drug Enforcement Administration (DEA), the medicine is not classified as a controlled substance.

Q: How is Valbenazine different from other medicines that treat movement disorders?

Valbenazine is classified as a Vesicular Monoamine Transporter 2 (VMAT2) inhibitor. The official information highlights its classification and notes its designation for once-daily dosing, distinguishing it from some related medicines.

Q: What does the term 'tardive dyskinesia' mean in simple language?

Tardive dyskinesia (TD) is a neurological condition characterized by involuntary and uncontrollable movements of the body. These movements often affect the face, such as lip smacking, puckering, grimacing, or rolling of the tongue, and can also involve the limbs. The condition is frequently linked to the long-term use of certain types of psychiatric medicines.

Q: What is Valbenazine’s classification or drug type?

Valbenazine is officially classified as a Vesicular Monoamine Transporter 2 (VMAT2) inhibitor. This pharmacological class is designed to help regulate the storage and release of certain chemical messengers, like dopamine, in the nerve cells of the brain.

Q: What are the most frequently reported side effects in research trials?

According to official documents summarizing clinical trial data, the single most common side effect reported by patients (occurring in 5% or more and at twice the rate of placebo) is somnolence. Somnolence is the medical term used to describe feelings of sleepiness or drowsiness.

Q: Does Valbenazine cause any problems with sleep?

Yes, problems with sleep are documented in the official safety information. Somnolence (sleepiness or drowsiness) is the most frequently reported adverse reaction. Additionally, some individuals in clinical studies reported difficulty falling asleep or staying asleep (insomnia).

Q: Is there a warning about suicidal thoughts or behaviors related to Valbenazine?

Yes, the official label contains a warning regarding the increased risk of depression and suicidal thoughts and behavior. This warning is highlighted specifically for patients being treated for chorea associated with Huntington’s disease. Official regulatory advice is that all patients using the medicine should be closely monitored for these changes.

Q: Does Valbenazine cure tardive dyskinesia, or just help manage symptoms?

Valbenazine is approved for the treatment of tardive dyskinesia (TD). Official documentation indicates its purpose is to manage and reduce involuntary movements. Clinical evidence shows that when the medicine is stopped, symptoms tend to return toward their original severity. Research indicates that the medication assists in the management of involuntary movements while it is being used.

Q: How long does it typically take for people to notice the effects of Valbenazine?

Studies and official information indicate that patients typically begin to notice the effects of the medicine within two weeks of starting treatment. More significant improvements in involuntary movements are commonly observed in clinical trials after approximately six weeks of consistent use.

Q: Does Valbenazine cause weight gain or weight loss?

Official prescribing information indicates that changes in weight, including increases in weight, have been reported as an adverse event in clinical studies. This is not listed as the most common side effect.

Q: Can older adults use Valbenazine?

Official regulatory data indicates that specific studies performed in the elderly population have not demonstrated specific problems that would limit the usefulness of the medicine in older adults. The need for dosage adjustments is typically based on factors such as organ impairment or co-administered medications, rather than age alone.

Q: Does Valbenazine change the way other medications are processed by the body?

Yes, valbenazine can affect the processing of some other medications. Both valbenazine and its active metabolite are processed by specific liver enzymes. Additionally, the medicine can inhibit a transport protein called P-glycoprotein (P-gp), which may affect the concentration of certain other co-administered drugs.

Q: Is there a generic version of Valbenazine available?

Valbenazine is currently marketed under the brand name Ingrezza. The medicine is protected by market exclusivity granted for its approved uses. Because of this, a generic version is not yet available on the market.

Q: What is the difference between Valbenazine and deutetrabenazine?

Both valbenazine and deutetrabenazine are classified as VMAT2 inhibitors, meaning they work by a similar mechanism to modulate neurotransmitters. A key factual distinction noted in the official prescribing data relates to administration: Valbenazine is approved for once-daily dosing, while deutetrabenazine is approved for twice-daily dosing.

Q: What is the purpose of the long-term studies on Valbenazine?

Long-term research studies were primarily conducted to evaluate the long-term safety profile of the medication over extended periods. A secondary purpose was to determine if the therapeutic improvements in involuntary movements were persistent in patients receiving treatment for periods exceeding one year.

Valbenazine capsules must be stored at controlled room temperature, specifically at 25 C (77 F), with permitted temperature excursions between 15 and 30 C (59 to 86 F). To maintain product integrity, the container must be kept tightly closed, and it is officially recommended to store the medication locked up.

Stability After Preparation

If the capsule contents are sprinkled over soft food, the resulting mixture should be swallowed immediately. If immediate use is not possible, the mixture may be stored at room temperature for a maximum of two hours, after which any unused portion must be discarded.

Disposal Requirements

Disposal of unused or expired Valbenazine must adhere to local, regional, national, and international regulations. Importantly, the medication should not be allowed to enter wastewater systems, such as drains or sewers, to prevent environmental contamination.